About Ellipses Pharma
Ellipses Pharma is a company based in London (United Kingdom) founded in 2015 by Christopher Evans. It operates as a Professional Services. Ellipses Pharma has raised $1.12 million across 2 funding rounds. Ellipses Pharma offers products and services including EP0031 (A400) and EP0062. Ellipses Pharma operates in a competitive market with competitors including TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
- Headquarter London, United Kingdom
- Founders Christopher Evans
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ellipses.life
- Social LinkedIn
- Legal Name Ellipses Pharma Limited
- Total Equity Funding$1.12M (USD)
in 2 rounds
- Latest Funding Round$750K (USD), Seed
Jun 2024
Products & Services of Ellipses Pharma
Ellipses Pharma offers a comprehensive portfolio of products and services, including EP0031 (A400) and EP0062.
A selective RET inhibitor for cancer treatment is developed.
An oncology drug candidate for cancer treatment is researched.
Funding Insights of Ellipses Pharma
Ellipses Pharma has successfully raised a total of $1.12M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $750 thousand completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.12M
- Total Rounds 2
- Last Round Seed — $750,000
- First Round $374,382
(May 2019)
All 2 funding rounds of Ellipses Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $750,000 | Seed | – | – | – |
| May 2019 | $374,382 | Seed | – | – | – |
People of Ellipses Pharma
20 people are tracked at Ellipses Pharma (15 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Christopher Evans | Founder & Chairman | Leadership |
Rajan Jethwa | CEO | Leadership |
Eden Demmisse | Head Of Finance | Leadership |
Sital Patel | Head Of Translational Medicine | Leadership |
Professor Tobias Arkenau | CMO And Global Head Of Drug Development | Leadership |
Ascanio Digiacomo | Director, Business Development And Corporate Strategy | Leadership |
Geoff Fisher | Director Of Clinical Strategy | Leadership |
Katie Stoddart | Director, Clinical Trial Delivery | Leadership |
Sue Brook | Associate Medical Director | Leadership |
David Cook | Chief Financial Officer | Leadership |
Nicky Pattrick | Chief Business Development Officer | Leadership |
Luke Slatford | Director Of Operations | Leadership |
Suzanne Wood | Chief HR Officer | Leadership |
Tiina Lugmayer | Personal Assistant To Chief Executive Officer | Leadership |
Martin Doorbar | Chief Development Officer (cdo): Non Clinical | Leadership |
Karry Ka Wai Wong Ca | Finance Manager | Team |
Sonia Serrano | Clinical Trial Manager | Team |
Charlotte Burmester | Associate Clinical Trial Manager | Team |
Sarah Jackson | General Counsel And Company Secretary | Team |
Arturo Maldonado | Associate Clinical Trial Manager | Team |
Complete people profiles for Ellipses Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ellipses Pharma
3 dated milestones of Ellipses Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Ellipses Pharma is founded.
- Funding First funding round of $374K.
- Funding Latest funding round, Seed, of $750K.
Competitors of Ellipses Pharma
Ellipses Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. | |
| boundlessbio.com | 2018 | San Diego, United States | $251.99M | 29 | Therapeutics for cancer are developed by targeting ecDNA. | |
| boltbio.com | 2015 | Redwood, United States | $177.49M | 94 | T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics. | |
| jacobiopharma.com | 2015 | Beijing, China | $55M | – | Small molecule therapeutics for cancer treatment are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| neophore.com | 2017 | Cambridge, United Kingdom | $44.56M | 10 | NeoPhore is focused on cancer neoantigen evolution therapies. |
Detailed competitors of Ellipses Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ellipses Pharma
The website of Ellipses Pharma (ellipses.life) receives about 4.3K visits a month.
- Monthly visits4.3K
▲ 15.8% vs previous month
Websites whose visitors overlap most with Ellipses Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lbic.com | 100% | – | #4,573,435 | View details | |
| insightbio.com | 98% | 5K | #3,682,821 | View details | |
| multus.bio | 97% | – | – | View details | |
| dnanudge.com | 94% | – | – | View details | |
| touchlight.com | 89% | 6.3K | #4,432,265 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Ellipses Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Ellipses Pharma
Complete news archive for Ellipses Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Ellipses Pharma
10 companies that operate in the same segment as Ellipses Pharma (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ellipses Pharma
Ellipses Pharma was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Ellipses Pharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Rajan Jethwa is the current CEO of Ellipses Pharma.
Ellipses Pharma is a funded company, having raised a total of $1.12M across 2 funding rounds to date. The company's 1st funding round was a Seed of $374.38K, raised on May 2019.
Ellipses Pharma, based in London, is dedicated to accelerating the development of cancer treatments through an innovative drug development model. Assets are selected through unbiased vetting to reduce risks, and uninterrupted funding is provided to minimize development time. The focus is placed on oncology, with solutions aimed at improving patient outcomes. Collaboration with partners like Kelun Biotech is maintained to advance drug applications, such as EP0031, for regulatory review in markets like China. Participation in initiatives like Rewriting Cancer, produced for UICC by BBC StoryWorks, is undertaken to highlight advancements in cancer care.
Ellipses Pharma's top competitors include Lyell Immunopharma, GigaGen and Shattuck Labs.
Ellipses Pharma offers EP0031 (A400) and EP0062.
Ellipses Pharma operates through Ellipses Pharma Limited.